Drug Trial Radar · NCT00003678
Tamoxifen in Treating Women With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20,000
Planned (sponsor's estimate)
Start
May 1991
Primary completion
Not stated
Sponsor
- Lead sponsor
- University Hospital BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of at least 2 years of tamoxifen with that of 5 additional years of tamoxifen in treating women who have breast cancer that has been surgically removed.
Conditions
- Breast Cancer
Interventions
tamoxifen citrateDrug
adjuvant therapyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Research UK Clinical Trials Unit - Birmingham
Birmingham, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.